Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
Status:
Completed
Trial end date:
2009-08-17
Target enrollment:
Participant gender:
Summary
This trial is a 52-week, open-label extension trial to investigate safety and to explore
efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706)
(NCT00482612) or 176002 (P05707) (NCT00506389). Participants who have completed Protocol
P05706 or P05707, and are willing to continue treatment with Esmirtazapine, can participate
in Protocol 176004 (P05708) after signing informed consent.